Recombinant IDH1 antibody (AA 281-414)

Catalog No. ABIN7873287

The Rabbit Monoclonal anti-IDH1 antibody is suitable to detect IDH1 in samples from Human. It has been validated for IHC (p).

Quick Overview for Recombinant IDH1 antibody (AA 281-414) (ABIN7873287)

Target: IDH1 (Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This IDH1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: IDH1-6806R

Product Details anti-IDH1 Antibody

Binding Specificity: AA 281-414

Purpose: IDH1 Antibody / Isocitrate Dehydrogenase (R132H mutant)

Purification: Protein A/G affinity

Immunogen: A portion of amino acids 281-414 was used as the immunogen for the IDH1 R132H antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the IDH1 R132H antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the IDH1 R132H antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for IDH1

Target: IDH1 (Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1))

Alternative Name: IDH1

Background: IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.

UniProt: O75874

Pathways: Warburg Effect